Astria Therapeutics, Inc. $ATXS Stock Position Lifted by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 185.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,471 shares of the biotechnology company’s stock after purchasing an additional 3,557 shares during the quarter. Farther Finance Advisors LLC’s holdings in Astria Therapeutics were worth $29,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. California State Teachers Retirement System grew its stake in shares of Astria Therapeutics by 9.9% in the fourth quarter. California State Teachers Retirement System now owns 32,561 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 2,935 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Astria Therapeutics by 3.1% in the first quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company’s stock worth $815,000 after purchasing an additional 4,562 shares in the last quarter. AlphaQuest LLC grew its stake in shares of Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 7,139 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Astria Therapeutics by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock worth $567,000 after purchasing an additional 7,756 shares in the last quarter. Finally, Brooklyn Investment Group grew its stake in shares of Astria Therapeutics by 1,079.6% in the first quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 7,957 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. JMP Securities increased their price target on Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 13th. Evercore ISI reissued an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a research note on Wednesday, October 1st. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. HC Wainwright raised their target price on Astria Therapeutics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Astria Therapeutics Stock Down 2.9%

Shares of NASDAQ ATXS opened at $7.47 on Wednesday. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.52. The company has a market cap of $421.61 million, a price-to-earnings ratio of -3.72 and a beta of 0.43. The business has a fifty day simple moving average of $7.01 and a 200-day simple moving average of $5.84.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. As a group, sell-side analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.